Needham Reiterates Buy on Ocular Therapeutix, Maintains $18 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 91.5%

Neg 0% Neu 91.5% Pos 0%

Needham analyst Serge Belanger reiterates Ocular Therapeutix (NASDAQ:OCUL) with a Buy and maintains $18 price target.

Comments

No comments yet. Be the first!